Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

NCT01216839 is registered in ClinicalTrials.gov with Sidnei Epelman as lead sponsor.

NCT NCT01216839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01216839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
Lead sponsor
Sidnei Epelman
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2011
Completion date
December 31, 2013
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory or relapsed rms and soft tissue sarcomas